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Abstract
Metabolomics and lipidomics are emerging methods for detailed phenotyping of small
molecules in samples. It is hoped that such data will: (i) enhance baseline prediction of pa-
tient response to pharmacotherapies (beneficial or adverse); (ii) reveal changes in metab-
olites shortly after initiation of therapy that may predict patient response, including ad-
verse effects, before routine biomarkers are altered; and( iii) give new insights into
mechanisms of drug action, particularly where the results of a trial of a new agent were
unexpected, and thus help future drug development. In these ways, metabolomics could
enhance research findings from intervention studies. This narrative review provides an
overview of metabolomics and lipidomics in early clinical intervention studies for investi-
gation of mechanisms of drug action and prediction of drug response (both desired and
undesired). We highlight early examples from drug intervention studies associated with
cardiometabolic disease. Despite the strengths of such studies, particularly the use of
state-of-the-art technologies and advanced statistical methods, currently published studies
in the metabolomics arena are largely underpowered and should be considered as
hypothesis-generating. In order for metabolomics to meaningfully improve stratified
medicine approaches to patient treatment, there is a need for higher quality studies, with
better exploitation of biobanks from randomized clinical trials i.e. with large sample size,
adjudicated outcomes, standardized procedures, validation cohorts, comparison witth rou-
tine biochemistry and both active and control/placebo arms. On the basis of this review,
and based on our research experience using clinically established biomarkers, we propose
steps to more speedily advance this area of research towards potential clinical impact.
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disease, diabetes
VC The Author 2016; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
International Journal of Epidemiology, 2016, 1–21
doi: 10.1093/ije/dyw271
Review
 Int. J. Epidemiol. Advance Access published October 27, 2016











Metabolomics is defined as the study of the metabolome:1,2
the small molecule complement of a biological system
(including drug- or microbiome-related metabolites).3,4 Mass
spectrometry (MS) and proton nuclear magnetic resonance
(1H-NMR) spectroscopy, utilizing targeted or untargeted
methods, are the most commonly used techniques.2,5–7
Lipidomics, a subset of metabolomics, is the study of trigly-
cerides, sphingomyelins, phosphatidylcholines and others,
using MS methods optimized for lipids.8,9 Epidemiologically,
metabolomic methods of phenotyping serum and plasma
samples in patients and populations are attractive because
they provide a large number of quantitative/semi-quantitative
measures relevant to current health status and future health
outcomes. The metabolite profile may be influenced by geno-
type, individual phenotypes, different environmental factors
(e.g. diet, activity, smoking, medical treatments) and differ-
ences in the microbiome.10 Therefore, metabolomics may
provide greater insight into mechanisms of drug action, par-
ticularly in different subgroups of patients.11
Pharmacometabolomics, the application of metabolo-
mics (and lipidomics) to the study and prediction of vari-
ation in drug response, is a relatively new direction.10,12
One potential application is that the baseline metabolite
profile (prior to pharmacotherapy) can predict drug re-
sponse, in terms of both efficacy and safety, helping to
stratify patients most likely to benefit from therapy or help-
ing to select dose or type of therapy.12,13 Alternatively, it
may be possible to use on-treatment changes in metabolites,
shortly after therapy has been initiated, to identify good
versus poor responders or those susceptible to adverse drug
reactions. These patients can then, potentially, be offered
alternative therapy or offered therapy at a more appropri-
ate dose, so-called early intervention pharmacometabolo-
mics.14 For example, prediction of drug-induced liver
injury (at baseline or early post-dose) is particularly rele-
vant to clinical trials since it is estimated that 40% of drug
candidates that are discontinued in the clinical trial phase
are as a result of hepatotoxicity.15,16 The ability to use
pharmacometabolomics to predict drug-induced liver injury
due to variation in metabolism of paracetamol was demon-
strated by Clayton et al., 2009.17 This was the first example
of pharmacometabolomics being used in humans.12,18
The value of randomized trial and
intervention study biobanks
The advantage of randomized controlled trials (RCT)
over observational studies is that they provide uncon-
founded estimates of the effect of an intervention. RCTs
with appropriate clinical outcomes, for example cardiovas-
cular disease (CVD) events linked to low-density lipopro-
tein–cholesterol (LDL-c) lowering, are described as having
the highest level of evidence for evaluating causal pathways
which integrate biomarkers.19 Even so, many trials are sus-
ceptible to weaknesses such as small sample size (with con-
sequent low statistical power to detect effects of the
intervention) and possible bias with, for example, open-
label design. Clinical trials can be designed to investigate
the effect of an intervention on surrogate outcomes and
metabolic pathways, or on clinically relevant endpoints.
Endpoint-driven trials are typically very large and can
allow the examination of treatment effects according to
various baseline characteristics and, where there are unex-
pected adverse or beneficial outcomes, novel predictors
can also be investigated. The clinical community would
Key Messages
• Metabolomics applied to clinical trial samples can help elucidate drug mode of action, but relevant cardiometabolic
examples are limited by small size and suboptimal study design.
• Clinical studies can also be used to identify novel predictors of important outcomes, in the same way as high-quality
observational studies.
• Metabolomics in pre-treatment samples can be tested to predict response to therapy (both desired and undesired),
but current data in cardiometabolic trials are limited.
• Early intervention metabolomics may identify changes in metabolites soon after initiation of therapy, which may pre-
dict later response to therapy or outcomes (both desired and undesired) but, again, current data from cardiometabolic
trials are limited.
• Future studies of cardiometabolic trials would benefit from better design (with greater exploitation of placebo-con-
trolled study samples and adjudicated outcomes), larger sample sizes, standardization of procedures, validation of
biomarkers in new cohorts and better testing of predictive abilities against current benchmarks to demonstrate real
clinical utility.
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welcome biomarkers that can predict variation in response
to therapy. The hope is that more people who would bene-
fit could be appropriately targeted whereas those who
would potentially suffer net harm would be spared such
therapy: so-called stratified (or personalized) medi-
cine.11,18,20 The use of a single (or a combination of) tech-
nique(s) that provides good coverage of clinically relevant
measures of small molecules, such as metabolomics, is thus
highly attractive. Even more so if those methods are quality
controlled, validated and provide robust identifications
and absolute quantitation.21 However, applications to pa-
tient care must be pragmatic and they must meaningfully
and cost-effectively guide care to be truly impactful.
Another value of major trials is that they typically offer
rich phenotyping of all participants including convention-
ally measured clinical biomarkers of interest. Therefore,
the added information obtained through more costly or
novel biomarker approaches, such as metabolomics, can
be readily measured against conventional biomarkers. This
provides a realistic benchmark to ensure that the novel bio-
marker(s) add value over and above routine measures and
are cost effective.22,23 Aside from randomized compari-
sons, the availability of adjudicated outcomes, as well as
prospective follow-up in trials, also provides the platform
for post hoc observational analyses. It is with this back-
ground that researchers value stored biobanks from such
large-scale clinical intervention studies to test novel bio-
markers for clinical value.
Examples of new knowledge from use of
routine biomarkers in clinical intervention
studies
To anticipate where metabolomics might be impactful,
and to make a useful comparison with existing metabolo-
mics data, evidence for conventional biomarker use in clin-
ical trials (including uncontrolled intervention studies of
single arms of these trials) ought to be considered.
So far, the clinical impact of routine biomarkers to pre-
dict the degree of treatment response in many fields has
been relatively modest.24 For example, some investigators
have argued that following initiation of statin therapy it
might be advantageous to track what benefit the therapy is
having on an individual patient’s risk profile. Although ini-
tial trial data putatively supported an early reduction in
high-sensitivity C-reactive protein (hsCRP) change as a pre-
dictor of subsequent cardiovascular benefit in addition to
LDL-lowering,23,25 further studies from our group and
others refuted this notion.26–28 Additionally, preliminary
evidence has suggested that liver function tests may predict
the degree of CVD benefit by statins, but this observation re-
mains unconfirmed.29 There are also suggestive trial findings
of differential effects based on baseline phenotypes with
other lipid-lowering agents, for example that the fibrate
class of drugs lowers cardiovascular risk more in those with
high triglyceride and low HDL-c, and that ezetimibe pre-
vents cardiovascular disease more in those with diabetes
than those without.30,31 Whether more detailed lipidomic/
metabolomic phenotyping at baseline, or on-treatment, can
better inform on benefits/risks of such therapies are ques-
tions of interest.
Regarding type 2 diabetes mellitus (T2DM), patients are
heterogeneous in terms of weight, insulin sensitivity, beta
cell function and renal and liver function. We have limited
information on which baseline phenotypes predict treat-
ment responses to a wide range of glucose-lowering drugs
with very different mechanisms. Ongoing work, such as in
the MASTERMIND study (interventional cross-over
study),32 will attempt to relate baseline phenotypes (includ-
ing metabolomics) to differential treatment responses to
three different classes of oral hypoglycaemic agents. The
potential to enrich existing diabetes trial biobanks with
metabolomics also exists and is likely to be pursued, with
multiple trials now reaching completion.
This article concentrates on metabolomic gains from tri-
als (including uncontrolled intervention studies), but the
utility of trial datasets or biobanks with the availability of
serially recorded routine biochemistry measures from indi-
viduals with adjudicated events should not be underesti-
mated. These have been used to inform on predictors of
events or to identify patterns of disease. For example, by ex-
ploiting the availability of serial 6-monthly liver function
tests from the West of Scotland Coronary Prevention Study
(WOSCOPS) (observational nested case control study, n ¼
946, 4.9 years follow-up), we noted that plasma levels of
the liver enzyme alanine aminotransferase (ALT) and fasting
triglyceride were the only significant independent predictors
of the development of T2DM. As previous data had linked
ALT levels to liver fat, these serial data were amongst the
first to suggest that hepatic fat accumulation may increase
before diabetes development.33 Such repeated measure data-
sets and biobanks provide excellent resources to better
understand the evolution of novel metabolomics pathways,
with potential for linking such changes to events of interest.
Similarly, trials have been used to provide more support for
cardiac biomarkers, such as N-terminal-pro-B-type natri-
uretic peptide (NT-proBNP), as independent predictors of
CVD events.34–36
Potential of metabolomics in drug trials
In terms of the investigation of mechanisms of drug action
or pharmacometabolomics, it is thought that changes in
metabolite concentrations after drug administration may
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be more pronounced (amplified) than changes in the
transcriptome or proteome.37–39
The fact that drugs are: (i) transported using metabolite
transporters (particularly membrane transporters);37 (ii) com-
monly metabolized using (phase I and II) enzymes used in
the metabolism of endogenous metabolites;40 and that they
(iii) target enzymes, receptors and transporters that evolved
for endogenous metabolites11 suggests that metabolite concen-
trations are important predictors of local drug concentration
and therefore drug response, and understanding of the
pathways involved in drug metabolism and the effect of drug
metabolites on endogenous metabolism is important in under-
standing drug mode of action as well as factors effecting drug
efficacy (ultimately concentration of active drug at the site of
action) and side effects.40
Measurement of only a few metabolites, for example
routine or emerging biochemical biomarkers, is often inad-
equate to interrogate drug effects, since most drugs affect
multiple interconnected metabolic pathways resulting in
multiple metabolic changes.11 The greater coverage offered
by metabolomics offers research potential. For this reason,
metabolomics has the potential for clinical applications,
but better quality studies are required to test this
notion.41,42
Genomics and pharmacogenomics studies have clearly
demonstrated that genetics alone cannot explain all the
variation in drug response.10 Pharmacoproteomics also has
potential, but so far has been described as lagging behind
genomics.20 Metabolomics has been described as ‘poten-
tially superior’ to genomics since it takes into account ex-
ogenous information [environmental influences (e.g. diet/
other pharmacotherapies) or interaction with the micro-
biome] in addition to genetic influences.10,15,18
Existing examples of use of metabolomics in
trials and intervention studies
We now describe early examples of the use of metabolo-
mics and/or lipidomics to investigate the effect of cardiome-
tabolic disease-related pharmacotherapies on metabolite
profiles in trials (including uncontrolled single-arm inter-
ventional studies), or to predict variation in drug response,
with some specific examples from the cardiometabolic
arena (Table 1). We excluded studies investigating only
drug effects on lipoprotein profiles (as previously re-
viewed43–45).
Strengths of metabolomic studies in trials to date
All of the studies used state-of-the art analytical methods
(Table 1). Many of the studies investigating pharmacome-
tabolomics or effects of pharmacotherapies on the
metabolome were well designed and included randomiza-
tion and control arms (Table 1). Many included important
endpoints (such as LDL-c lowering after statin therapy);
however, only one had a hard endpoint (CVD outcome in
glipizide-treated patients).46 A number of studies included
routinely measured biomarkers for comparison.46–55
The majority of studies also adjusted for multiple statistical
comparisons (Table 1). Some performed internal model
validation55,56 and two studies performed external model
validation.57,58 Some studies also combined metabolomics
data with genomic and proteomic data.55,57,59
Hypothesis-generating/post hoc studies of the
effect of cardiometabolic drugs on metabolomics
biomarkers
The majority of studies that have measured metabolomics
in samples from clinical intervention studies are the result
of post hoc or hypothesis-generating studies (Table 1), as
often recognized by the authors themselves. In most cases,
published data to date are from studies that are small in
size (the largest being a study of 272 adults51), conse-
quently they may be limited in power. Despite this some
have shown some promise for the future of metabolomics,
and the clear need for hypothesis-generating research has
been highlighted.60,61 However, we also need to acknow-
ledge that a higher standard of research is now required to
advance the field to a degree where real-world clinical ap-
plications of metabolomics can be considered. We there-
fore highlight examples of weaknesses in existing research
that might be improved in the future.
Most studies have investigated how a specific drug may
alter metabolic profile (mode of actions studies), but little
else (Table 1). Only a few have linked any specific metab-
olite to clinical outcomes, or to prediction of benefit or
harm, primarily due to lack of power. Often only surrogate
markers for clinical outcomes were used: LDL-c lowering
as a marker for statin-related CVD reduction,62–65 ALT as
a marker for liver injury,59 platelet aggregation as a marker
for anti-platelet effects57,58 or low cardiac output as a
marker for myocardial protection,52 for example. Whereas
these studies are of interest, they are currently limited in
terms of clinical translation.66
Few studies compared metabolite-based biomarkers
with routine measures (Table 1).47–52,55 For example, in a
lipidomic study of rosuvastatin’s effect in healthy volun-
teers, a number of lipids were found to be decreased.8
Some decreases will be entirely dependent on increased
clearance of LDL particles as a result of rosuvastatin ther-
apy and therefore, in isolation, such data provide limited
additional insight into mechanisms of rousuvastatin or
clinical implications of treatment. In a previous lipidomics
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study of the effect of simvastatin in men with mixed dysli-
pidaemia, reductions in fatty acids (FAs) were associated
with increased clearance of LDL particles; no reductions in
FAs were observed in non-responders who did not have a
decrease in LDL-c.67 Again, such findings are hypothesis-
generating and require further detailed and robust study.
Approximately half of included studies were post hoc
analysis of interventional studies used for observational
investigations (no longer placebo-controlled) or are
based on analysis of single-arm interventional studies
(Table 1).8,49–51,57–59,62–65 Although they are included in
this narrative review, it should be noted that evidence
from such studies is potentially biased or confounded.
For example, in an investigation of the effect of rosuvas-
tatin on lipidomic profile, changes were compared with
baseline concentration only,8 and in a study of metfor-
min’s effect on metabolite profile, metformin-treated in-
dividuals were compared with individuals with no
therapy.68 Atenolol is a commonly used selective adren-
ergic B1 receptor antagonist that is known to increase the
risk of hyperglycaemia, impaired fasting glycaemia (IFG)
and diabetes mellitus50 (Table 1). In a nested case-
control study of the Framingham Offspring Study, a com-
bination of five amino acids was found to modestly pre-
dict the risk of diabetes or insulin resistance.69 Using a
hypothesis-driven approach to determine if these same
amino acids predicted risk of IFG after atenolol therapy,
other researchers performed amino acid analysis
(described as targeted metabolomics) in 122 adults
treated with atenolol for a mean of 9 weeks as part of a
nested case-control study of an interventional study.50
They demonstrated that the same amino acids could pre-
dict individuals most likely to develop IFG after atenolol
treatment. The authors suggested that treatment with
drugs such as atenolol may be an environmental trigger
in these at-risk individuals. However, as the study only
included participants from the atenolol arm (with no
control arm), it is not possible to speculate on how many
individuals would have developed IFG anyway, nor
whether usual predictors of diabetes would have given
the same or better information on diabetes prediction.
Some studies included only healthy individuals (for ex-
ample studies of fenofibrate49 and aspirin57,58). Changes in
metabolite concentrations in healthy individuals may differ
from changes in metabolite concentration in intended recipi-
ents of pharmacotherapy.51 Other studies were limited by
the availability of time-matched samples. In a study of xime-
lagatran toxicity, samples from cases of drug-induced liver
injury were not available from controls at the same time
points, so causal inferences cannot be made with any confi-
dence.59 In some studies, patients in different treatment
arms were not well matched at baseline, for example gender
imbalance in a study of atenolol in African Americans ver-
sus Caucasians,51 and age imbalance between healthy vol-
unteers and patients with T2DM in a study of
rosiglitazone.70 There is also the strong likelihood of publi-
cation bias, with negative studies being very slow to publish
or left unpublished.71 Hence, most of the studies published
to date should, at best, be described as hypothesis-
generating, and few as yet have added clinically meaningful
insights.
Finally, a recent observational study took advantage of a
parallel genetic analysis to show almost identical changes in
lipoprotein and lipidomic profiles with statin use (versus
non-use) and corresponding genetic instruments (HMGCR
rs12916 variant known to mimic HMGCR inhibition).72
No robust changes were observed for the metabolites meas-
ured (amino acids, ketones, glycolysis- and gluconeogenesis-
related metabolites) in the statin-treated or the rs12916
variant groups, suggesting minimal pleiotropic effects. This
study is therefore an exemplar for future combined genetic/
phenotyping studies, so called ‘natural’ or in silico clinical
trials, to determine metabolomics effects of drugs.73
Examples of metabolomics studies limited by lack
of clinical utility
As is the case for many drugs, there is clinical variation in the
effects of statins on LDL-cholesterol. In one study, decreases
in LDL-c ranged from less than 5% to more than 60% on
simvastatin 40 mg daily (however, LDL-c lowering was as
expected in the majority, i.e. > 30% in> 75% of partici-
pants, and > 20% in> 90% of participants) even when
concordance with therapy was apparently accounted for.65
Investigators have therefore sought to determine whether
metabolomics can help predict degree of statin efficacy
in terms of LDL-cholesterol lowering (Table 1).62–65,74,75
Here, preliminary evidence indicates secondary bile acids
and amino acids produced by the gut microbiome may con-
tribute to the inter-individual variation in LDL-c lowering re-
sponse.62–64 Baseline concentrations of secondary bile acids
and other metabolites have been found to predict the circu-
lating statin concentration and the degree of LDL-c lowering
by statins,62,63,65 but more robust studies are needed to con-
firm these findings.
Whereas these studies are of academic interest, our view
is that the use of pharmacometabolomics in prediction of
statin LDL-c-lowering response in clinical practice is likely
to be impractical, given the huge numbers of patients eli-
gible for statin therapy, the low cost of treatment, the safety
of statins and the LDL-c lowering that is likely to occur in
the vast majority. Patients routinely start on a standard sta-
tin dose (e.g. atorvastatin 20 mg/day for primary prevention
and atorvastatin 80 mg/day for secondary prevention)
14 International Journal of Epidemiology, 2016, Vol. 0, No. 0









unless there is potential for drug interaction or there appears
a high risk of adverse events.76 If a patient is found to have
responded poorly to statin therapy, i.e. a lack of LDL-c
reduction (or better non-HDL-c change) using routine
biochemistry analysis,77 adherence and diet/lifestyle changes
are discussed and the dose can be increased. It is unlikely
that the current cost of predicting patient response using
metabolomics, even if this were possible with a high degree
of accuracy, whether at baseline or early post intervention,
would be clinically effective or cost effective in this regard.
Similar limitations have been outlined for the use of
pharmacogenomics on the prediction of optimal statin ther-
apy.78 Interestingly, the Clinical Pharmacogenetics
Implementation Consortium has issued guidelines for using
SLCO1B1 to inform simvastatin dose, but only when gen-
etic data are already available.79 In our view, metabolomics
measurements to predict response to therapy may well have
a place with medicines where risk/benefit is more closely
balanced, and where response to therapy is more variable.
We believe that there is an important distinction to be made
between cheap, safe and clinically effective pharmacothera-
pies such as statins and more expensive, risky pharmaco-
therapies that would more likely benefit from tailoring,
such as oncotherapy. In such situations a strong case can be
made for detailed phenotyping to allow selection of individ-
uals most likely to benefit.
Certainly there is a variation in response to statins and this
does correlate with efficacy in terms of CVD risk reduction.80
However, in many cases where expected response to statin
therapy is not observed, poor adherence to therapy or discon-
tinuation of therapy is the usual cause.81,82 Such cases will not
be helped by pharmacometabolomics. It is also important to
note that although on-treatment reduction in LDL-cholesterol
is only one measure of statin effectiveness, it is a simple, cheap
and effective measure of response (and adherence) to statin
therapy.83
Most importantly, we note that there are currently no
lipid-modifying therapies that can compete with statins in
terms of both clinical and cost effectiveness. There is no evi-
dence that a patient who does not respond well to a statin
would respond better to ezetimibe or bile acid sequestrants.
Withholding statin therapy based on pharmacometabolo-
mics and treating with such alternatives would likely be un-
ethical. New LDL-cholesterol lowering therapies such as
PCSK9 inhibitors may be more widely prescribed in future
(currently limited to patients with familial hypercholestero-
laemia and those receiving statin therapy for secondary pre-
vention who do not achieve LDL-c targets).80 These agents
have to be injected, are hugely expensive and have not yet
been proven to reduce CVD risk. Giving patients such thera-
pies based on pharmacometabolomics results is again
unlikely, in our view. It remains to be shown (in clinical
trials) that pharmacometabolomics is superior to monitoring
of LDL-cholesterol response, and we would argue that given
the low costs and effectiveness of statin therapy, and the low
cost of monitoring, this is unlikely to be the case.
Despite our reservations concerning pharmacometabolo-
mics for the purpose of predicting statin efficacy, we
agree that pharmacometabolomics of statin therapy may
have a role in identifying potential biomarkers of myopathy
(Table 1).9,75,84 UPLC/MS lipidomics identified changes in
phosphatidylethanolamine, long-chain fatty acids, phos-
phatidylcholine and cholesterol esters, which differed after
simvastatin (80 mg/day) compared with atorvastatin
(40 mg/day) for 8 weeks in a placebo-controlled study.
These drug-specific changes correlated with muscle expres-
sion of arachadonate 5-lipoxygenase-activating protein,
involved in pro-inflammatory pathways. The authors
postulated that the metabolomic approach may provide a
sensitive marker of statin-induced changes in muscle and
could be used to identify patients at risk of myopathy. The
availability of a placebo control group is certainly a
strength of the study. However, the study included a small
number of participants (37 in total) and results were not
corrected for false discovery rate (FDR). Moreover, the
study did not include any participants with previous myop-
athy on a statin and a study in this population would be
valuable. Even if some markers are eventually validated as
useful predictors of myopathy, the health economic benefits
of metabolite measurement would need to be established.
Nevertheless, this is an interesting area of future research
and may be applicable, in future, to high-risk individuals
such as those with impaired hepatic or renal function, those
on concomitant drug therapy known to increase the risk of
myopathy or those with a family history of statin intoler-
ance or muscle disease.83 Clearly, for other drugs/interven-
tions where immediate optimal therapy is more critical, or
where risk/benefit considerations are more complicated,
pharmacometabolomic-guided therapy may be more
valuable.
Pragmatic limitations in applying
metabolomics to large intervention studies
and routine clinical use
Analytical challenges
There are many challenges in metabolomics and lipidomics
(Table 1).10,85 Most result from the complex mixture of
metabolites found in biological samples such as serum and
urine. Metabolites have a diverse range of physiochemical
properties; therefore no single method can detect all of
them.21 There is a limited ability to detect low concentra-
tion metabolites due to limitations in sensitivity,
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particularly with 1H-NMR metabolomics, narrowing the
detectable dynamic range (ratio of highest versus lowest
concentration: e.g. pM to mM). Problems with metabolite
identification are common, partly due to limited availability
of standards needed to confirm metabolite identity.
Absolute quantitation, particularly in untargeted MS meth-
ods, is also problematic, again partially due to limited
availability of stable isotope-labelled standards needed for
quantification by MS due to variability in ion suppression
and instrument stability. Inter-batch variation is an issue in
MS metabolomics of studies with a large number of sam-
ples.86 Artefactual results due to variation in sample collec-
tion, storage and preparation are also known to be a
problem for both metabolomics and routine clinical chem-
istry methods.5 High cost can be an issue, in particular for
MS-based studies, and this often means smaller sample sizes
with reduced power are often used, limiting the information
gained.85 The benefits and limitations of MS and 1H-NMR
metabolomics have been highlighted in a number of studies,
and are generally described as complementary.21,87,88
Some of these problems can be overcome, and consider-
able effort has gone into optimizing available methods.
Primarily, the analytical platform that naturally best meets
the requirements to answer a specific research question
should be chosen. Decisions on which analytical technique
to use will often be pragmatic, based on instrument avail-
ability, costs, sample volumes or the need for absolute
quantitation, high sensitivity, high throughput or improved
coverage.21,89,90 Problems resulting from lack of coverage
of the metabolome can be minimized by employing mul-
tiple analytical techniques in tandem as demonstrated in
several of the studies described.55,59,62–65,68 Alternatively,
multiple extraction techniques or columns and mobile
phases can be employed in LC-MS. However, this can be-
come costly and time consuming.89 Additionally, the drug
of interest may direct the analytical technique chosen, for
example the mechanism of action of lipid-lowering thera-
pies may be more usefully probed using lipidomic methods
rather than methods optimized for polar metabolites.
However, the bile acid and simvastatin example demon-
strates that this is not always the case.62,64 Problems with
identification will be improved as spectral databases such
as MassBank and the Human Metabolome Database
(HMDB) continue to grow.91,92 Metabolites can also be
identified by following up studies with more detailed meth-
ods such as two-dimensional NMR or high mass accuracy
MS with fragmentation (MSn).40,89 Methods are emerging
which allow absolute quantitation of a large number of
metabolites by MS by including large numbers of labelled
internal standards [Biocrates (current maxmum 180 metab-
olites and lipids) and Mass Isotopomer Ratio Analysis of
U-13C-Labeled Extracts (MIRACLE)]93,94 Inter-batch
variation in MS can be corrected for statistically using
pooled quality control samples and statistical normalization
methods,9,86 although this approach is only satisfactory for
research (not clinical) purposes. Artefacts resulting from
variation in sample handling can be minimized by the im-
plementation of strict standard operating procedures.5
Advances in automation (robotic sample preparation, han-
dling and delivery as well as automated data processing)
are allowing metabolomics to be used in large-scale stud-
ies.91 This has contributed to the initially high costs associ-
ated with metabolomics being reduced.91 Costs can be
further reduced by choosing high-throughput methods, for
example, the 1H-NMR method described by Soininen
et al., 2015, which has been used in a large number of
observational studies.42 However, it should be noted that
this method quantifies only 18 metabolites due to limited
sensitivity of 1H-NMR, the other metabolic measures being
lipoprotein and lipid measures.21,42 Other methods that
have been used in large-scale observational studies include
the Metabolon method.95 This method is comparatively ex-
pensive and provides only relative (not absolute)
quantification.95
Accepting that every technique, including those in rou-
tine biochemistry, has its limitations, we expect that many
of these issues will not necessarily be overcome but mini-
mized. There will always be trade-off between sensitivity,
metabolite coverage and precision.89
Interpretative challenges
There are multiple challenges in the interpretation of metab-
olomics studies (Table 1). There is the clear potential risk of
false-positives and over-fitting models, particularly if there
are a large number of ‘metabolite measures’ in relation to
sample size.96 Another statistical issue relates to the analysis
of multiple biomarkers in data that are highly correlated,
and avoiding co-linearity in prediction models.
False-positive results can be minimized by appropriate
statistical correction for multiple comparisons and by valid-
ation of models.91,96,97 Over-fitting of models can be
reduced by cross-validation of the model (using an excluded
test set) or, preferably, by validation in an independent ex-
ternal dataset (a separate follow-up study analysed separ-
ately).91,98 Co-linearity issues can been addressed using
multivariate methods, such as principal component analysis
(PCA) and orthogonal partial least squares discriminant
analysis (OPLS-DA).99 However, such methods are not al-
ways appropriate, depending on the research aims.97,98
Highly correlated metabolites can also be removed from it-
erative models.9 More complicated statistical strategies for
dealing with ’omic data (such as elastic net) have been
reviewed.100
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As clinical trial samples are very valuable and limited,
careful use is essential. Most importantly, the studies need to
be backed up by relevant clinical or mechanistic questions to
avoid generating a series of results that, although of academic
interest, do not advance clinical utility or provide mechanistic
insights. This can be achieved by interdisciplinary work.22
Many of these obstacles (both analytical and interpret-
ative) are not unique to metabolomics, and also apply to
emerging chemistry-based markers, proteomics, transcriptom-
ics and genomics.19,79,101 Therefore, both analytical technolo-
gies and computational methods are constantly advancing
and evolving. It should be stressed that despite these limita-
tions, studies have shown the power of metabolomics in
mechanism of action studies to generate novel hypothesis.10
How can real gains be made?
The issues described above suggest that considerable work
is required to better test the clinical utility of metabolomics
in clinical trial datasets. We now provide a list of recom-
mendations, in part mirroring a roadmap for implementa-
tion of proteomic biomarkers which is equally valid for
metabolic biomarkers.22
i. Analysis of existing larger trials as well as trials
including a wide range of age groups, ethnicities and
other characteristics, or at least representing the
population the drugs are expected to be prescribed
for, rather than only healthy volunteers.
ii. Use of data from existing trials with hard endpoints
and not just surrogate endpoints. This allows testing
whether pharmacometabolomics can predict the out-
comes that really matter in clinical practice.
iii. Use of data from trials with a control arm: either pla-
cebo-controlled or a new therapy compared with the
current gold-standard pharmacotherapy.
iv. Comparison of predictive abilities of potential new
biomarkers versus gold-standard conventional bio-
markers. Such an approach enables proper assessment
of incremental utility gained by novel biomarkers
over and above established tests.
v. Standardization of methods, including collection and
storage of samples, to lessen the effect of measure-
ment artefacts on data.
vi. Implementation of fully validated methodology with
absolute quantification, batch correction and confi-
dent identification where possible, to yield data that
can be trusted, compared between studies and inter-
preted (biologically) more easily.
vii. Whenever possible, validation of any novel findings
in an independent cohort to give added confidence
that results are robust and generalizable.
viii. Economic analysis to estimate whether any incremen-
tal benefits justify the increase in costs or to determine
realistic prices to enable clinical consideration.
ix. Dissemination, communication and working with a
range of stakeholders: scientists, patients, clinicians,
clinical scientists, regulatory bodies, expert committees,
statisticians, health economists, pharmaceutical/biotech-
nology companies and biobanks. This ensures studies
are relevant, well designed and conducted, and useful.
Conclusion
Metabolomics has been applied to biobanked samples from
clinical trials in recent years, but selected studies have typic-
ally been of a small scale and focused on surrogate out-
comes, with the consequence that published evidence has
indicated at best only modest potential. If such findings can
be extended and properly validated, there remains a poten-
tial for metabolomics to aid better tailoring of drugs to pa-
tients (beyond those enrolled in clinical trials). Accordingly,
pharmacometabolomics has been described as a ‘potential
gateway’ to stratified medicine.12,13 However, the useful-
ness of pharmacometabolomics in clinical trials will likely
vary from drug to drug, depending on how well safety or ef-
ficacy can be predicted from simpler tests, what other op-
tions are currently available and the cost of sample
analysis.12,102 Current evidence in this area remains
exciting but is largely at the hypothesis-generating or proof-
of-concept stage. As such, further assessment of its use is
required in a larger number of robust studies or trials.
For real advances to be made, investigators with metabolo-
mics expertise need to work with clinicians and statisticians
to: (i) develop rigorous experimental study designs; (ii) to iden-
tify the best biobanks to exploit; and (iii) to carefully outline
the key clinical questions that could be usefully addressed by
metabolomics at the very beginning of the project.
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